Jinling Pharmaceutical maintains a strong liquidity position with a current ratio of 3.89, indicating the company can cover its short-term obligations more than three times over. However, the compa…
Cachet Pharmaceutical maintains a debt-to-equity ratio of 0.49, indicating a relatively conservative capital structure. The company's liquidity position is assessed as medium, with a current ratio…
Harbin Medisan's capital structure is characterized by a debt-to-equity ratio of 0.43, indicating a relatively conservative leverage position compared to the industry median. The company's liquidit…
The company maintains a strong liquidity position, with cash and equivalents amounting to KRW 31,809 million, which is 34% of total assets. However, the free cash flow is negative at KRW -17,043 mi…
The company's capital structure is characterized by a debt-to-equity ratio of 1.15, indicating a moderate level of leverage. Its liquidity position is assessed as medium, with a current ratio of 1.…
JW Shinyak Corp maintains a capital structure with a debt-to-equity ratio of 1.74, indicating a relatively high reliance on debt financing. The company holds 20.31 billion KRW in cash and equivalen…
China Health Group Ltd has a market capitalization of HKD 776.8 million, with a market price of HKD 0.56 per share. The company has 1.39 billion shares outstanding, with no dilution observed betwee…
The company maintains a strong liquidity position, with a current ratio of 4.27, indicating that it has more than four times the current assets to cover its current liabilities. Its cash and equiva…
Nibec maintains a strong capital structure with a debt-to-equity ratio of 0.22, indicating a relatively low reliance on debt financing. The company's liquidity position is characterized as medium r…
The company maintains a liquidity position with a current ratio of 1.19, indicating a moderate ability to meet short-term obligations. Its price-to-book ratio is 1.62, suggesting that the market va…
The company's capital structure is characterized by a very low debt-to-equity ratio of 0.0, indicating a nearly debt-free balance sheet. Total equity of 1.64 billion CNY supports total assets of 1.…
EPS Bio Technology Corp maintains a strong liquidity position, with a current ratio of 3.46, indicating the company can easily cover its short-term liabilities with its current assets. The company'…
Jinyao Pharmaceutical maintains a relatively conservative capital structure, with a debt-to-equity ratio of 0.22, indicating a low reliance on debt financing. The company's liquidity position is ch…
Shanghai New World Co Ltd maintains a relatively strong liquidity position, with a current ratio of 1.6, indicating the company can cover its short-term liabilities with its short-term assets. Howe…
The company's capital structure is characterized by a debt-to-equity ratio of 0.89, indicating a moderate level of leverage. Its liquidity position is assessed as medium, with a current ratio of 0.…
China Health Group Inc has a market capitalization of 123,423,605.84 CNY, with a market price of 0.124 CNY per share. The company has 995,351,660 basic and diluted shares outstanding, indicating no…
The company maintains a strong liquidity position, with cash and equivalents amounting to ¥5.698 billion, representing 20.7% of total assets. The absence of long-term debt and a debt-to-equity rati…
BIOCTAVE INC has a strong liquidity position, with a current ratio of 5.01, indicating the company can cover its short-term liabilities more than five times over with its current assets. The compan…
Modernland Realty Tbk PT has a liquidity risk profile that is currently rated as medium, with a debt-to-equity ratio of 1.94 and a current ratio of 0.84, indicating that the company's short-term li…
MEDICAB.MX has a basic and diluted share count of 107,938,972, indicating no dilution from stock options or convertible securities. However, liquidity risk could not be assessed due to the absence…
Nordson Corp (NDSN.O) is currently classified as Biotechnology within Biotechnology (Healthcare). Classification confidence: 0.66 (rule-based classification). Capital structure on the latest snapsh…
NatureCell maintains a strong liquidity position, with a current ratio of 7.39, indicating that its current assets significantly exceed its current liabilities. The company holds KRW 26.71 billion…
China NT Pharma Group Co Ltd has a market capitalization of 569,398,616.4 CNY, with a market price of 0.6 CNY per share. The company has 948,997,694 basic and diluted shares outstanding, indicating…
AbClon Inc maintains a strong liquidity position with KRW 39.01 billion in cash and equivalents, representing 55.2% of total assets. The company's debt-to-equity ratio of 0.12 indicates a conservat…
The company maintains a strong liquidity position, with a current ratio of 3.7, indicating a robust ability to meet short-term obligations. Its cash and equivalents amount to 1,843,945,000 JPY, sig…
Youngy Health maintains a strong liquidity position, with a current ratio of 6.49, indicating the company can easily cover its short-term liabilities with its current assets. The company's liquidit…
Center Laboratories Inc exhibits a strong capital structure with a debt-to-equity ratio of 0.18, indicating a relatively low reliance on debt financing. The company's liquidity position is characte…
The company's capital structure is characterized by a strong liquidity position, with cash and equivalents amounting to ¥1.7 trillion, which is significantly higher than its total liabilities of ¥1…
The company has a strong liquidity position, with cash and equivalents amounting to ¥170,979,000,000, significantly exceeding its total liabilities of ¥73,401,200,000. The current ratio of 9.91 ind…
6576.TWO has a liquidity ratio of 3.44, indicating a strong ability to meet short-term obligations, but the company reported negative operating and free cash flows of -842,227,000 TWD and -830,516,…
The company maintains a debt-to-equity ratio of 0.99, indicating a balanced capital structure with a moderate level of leverage. Its liquidity position is characterized by a current ratio of 1.58,…
(a) Capital structure and liquidity: The company maintains a conservative balance sheet with total assets of $366.3 million and total liabilities of $17.3 million, resulting in a debt-to-equity rat…
HONG.KL maintains a strong liquidity position with a current ratio of 11.82, indicating the company can easily cover its short-term liabilities with its current assets. However, the company's opera…
IAN.CD's capital structure is highly leveraged, with total liabilities of $359.03 million and total equity of -$103.04 million, resulting in a debt-to-equity ratio of -1.88. The company's liquidity…
Jupiter Neurosciences operates with a highly leveraged capital structure, as evidenced by its negative total equity of $1.83 million and a debt-to-equity ratio of -2.89. The company's liquidity pos…
UG Healthcare's capital structure is characterized by a lack of detailed liquidity metrics, as liquidity risk could not be assessed due to missing balance-sheet inputs and no going-concern language…
Verici DX PLC has a market price of 0.425 USD and a market capitalization of 643,192,503.98 USD, indicating a relatively small market presence. The company's liquidity risk could not be assessed du…
The company maintains a strong liquidity position, with cash and equivalents amounting to KRW 29,090,832,980 and a current ratio of 1.64, indicating a solid ability to meet short-term obligations.…
The company's capital structure is characterized by a debt-to-equity ratio of 0.22, indicating a relatively low reliance on debt financing. However, the company's liquidity position is assessed as…
The company maintains a capital structure with a debt-to-equity ratio of 1.06, indicating a moderate reliance on debt financing. Its liquidity position is characterized by a current ratio of 0.79,…
MedicalSystem Biotechnology Co Ltd maintains a strong liquidity position, with a market capitalization of 3.54 billion CNY and an enterprise value to revenue ratio of 2.34, indicating a relatively…
4139.TWO has a debt-to-equity ratio of 1.13, indicating a moderate level of leverage, while its current ratio of 0.57 suggests potential liquidity constraints. The company's free cash flow of 97,19…
Precision System Science Co Ltd maintains a strong liquidity position, with cash and equivalents amounting to ¥20,496,960,000, which significantly exceeds its total liabilities of ¥2,177,686,000. T…
The company's capital structure is characterized by a debt-to-equity ratio of 1.84, indicating a significant reliance on debt financing. Its liquidity position is moderate, with a current ratio of…
Holista CollTech operates with a capital structure that includes 367,834,364 basic and diluted shares outstanding, indicating no immediate dilution pressure from share issuance. The company's liqui…
Harvard Apparatus Regenerative Technology Inc has a highly leveraged capital structure, with a debt-to-equity ratio of 2.86 and a current ratio of 0.28, indicating significant liquidity constraints…
Vidipha Central Pharmaceutical JSC maintains a capital structure with a debt-to-equity ratio of 0.46, indicating a relatively balanced approach to financing. The company's liquidity position is cha…
ZOMDF.PK has a capital structure with no long-term debt and a debt-to-equity ratio of 0.0, indicating a fully equity-funded operation. The company holds $9,017,000 in cash and equivalents, and its…
Aimed Bio Inc maintains a strong liquidity position, with a current ratio of 31.43, indicating a significant buffer of current assets over current liabilities. The company's cash and equivalents am…
Hunan Hansen Pharmaceutical Co Ltd maintains a strong liquidity position, with a current ratio of 4.58, indicating that it has sufficient current assets to cover its current liabilities. The compan…
Hainan Shuangcheng Pharmaceuticals Co Ltd has a market capitalization of 4.77 billion CNY and a price-to-earnings ratio of 250.43, indicating a high valuation relative to its earnings. The company'…
The company's capital structure is characterized by a low debt-to-equity ratio of 0.1, indicating a conservative leverage profile. Its liquidity position is assessed as medium, with a current ratio…
Chongqing Pharscin Pharmaceutical Co Ltd maintains a strong liquidity position, with a current ratio of 5.05, indicating that it has more than five times the current assets to cover its current lia…
Allmed Medical Products Co Ltd maintains a relatively strong liquidity position, with a current ratio of 1.49, indicating that it has sufficient short-term assets to cover its short-term liabilitie…
The company maintains a relatively strong liquidity position, with a current ratio of 1.96, indicating that it has sufficient current assets to cover its current liabilities. However, the company h…
The company maintains a relatively strong liquidity position, with a current ratio of 4.22, indicating that it has sufficient current assets to cover its current liabilities multiple times over. Ho…
Kyung Nam Pharm Co Ltd has a liquidity position that is marginally stable, with a current ratio of 1.04, indicating that its current assets slightly exceed its current liabilities. However, the com…
Hwail Pharm Co Ltd maintains a strong liquidity position, with a current ratio of 21.74 and cash and equivalents amounting to KRW 61,468,769,170, which significantly exceeds its total liabilities o…
The company maintains a relatively strong liquidity position, with a current ratio of 5.44, indicating that it has more than five times the current assets to cover its current liabilities. However,…
Vivozon's capital structure shows a debt-to-equity ratio of 0.38, indicating a relatively conservative leverage position compared to the industry median of 0.52. The company's liquidity position is…
The company's capital structure is characterized by a debt-to-equity ratio of 0.37, indicating a relatively conservative leverage position compared to industry norms. However, the company's liquidi…
The company maintains a strong liquidity position, with a current ratio of 12.95, indicating a significant buffer of current assets relative to current liabilities. The debt-to-equity ratio is 0.02…
The company's capital structure is characterized by a high debt-to-equity ratio of 1.22, indicating a significant reliance on debt financing. With total liabilities of KRW 105.52 billion and total…
The company's capital structure is characterized by a debt-to-equity ratio of 0.46, indicating a relatively conservative leverage position compared to industry norms. However, the company's liquidi…
Gencurix Inc has a market capitalization of KRW 45,153,062,850 and a price-to-book ratio of 4.26, indicating that the market values the company at a premium to its book value. The company's liquidi…
The company's capital structure is characterized by a low debt-to-equity ratio of 0.2, indicating a conservative leverage position relative to its equity base. Its liquidity position is strong, wit…
BNC Korea Inc maintains a strong liquidity position, with a current ratio of 7.28, indicating a robust ability to meet short-term obligations. The company's cash and equivalents amount to KRW 79,21…
The company's capital structure is characterized by a debt-to-equity ratio of 1.02, indicating a relatively balanced mix of debt and equity financing. However, the company's liquidity position is w…
DRGem Corp maintains a relatively strong liquidity position, with a current ratio of 2.4, indicating the company can cover its short-term liabilities with its short-term assets. However, the compan…
IntoCell Inc operates with a highly leveraged capital structure, as evidenced by a price-to-book ratio of 19.12 and a debt-to-equity ratio of 0.41, indicating a relatively conservative debt load co…
AptaBio Therapeutics Inc has a market capitalization of KRW 184.85 billion and a price-to-book ratio of 3.21, indicating that the market values the company at a premium to its book value. The compa…
The company's capital structure is characterized by a debt-to-equity ratio of 0.37, indicating a relatively conservative leverage position compared to industry norms. However, the company's liquidi…
Huaren Pharmaceutical has a market price of 2.82 CNY per share, with a market capitalization of 3.33 billion CNY. The company's price-to-book ratio is 3.98, and its price-to-tangible-book ratio is…
Guangzhou Wondfo Biotech Co Ltd maintains a conservative capital structure with a debt-to-equity ratio of 0.11 and a current ratio of 3.18, indicating strong short-term liquidity coverage. The comp…
Gansu Longshenrongfa Pharmaceutical Industry Co Ltd has a debt-to-equity ratio of 0.24, indicating a relatively conservative capital structure with limited leverage. The company's liquidity positio…
Jiangsu Apon Medical Technology Co Ltd has a market capitalization of 2.9999 billion CNY and a price-to-book ratio of 4.49, indicating a premium valuation relative to its book value. The company's…
Zhejiang Wecome Pharmaceutical Co Ltd has a market price of 32.51 CNY per share, with a market capitalization of 4.71 billion CNY. The company's price-to-book ratio is 5.17, and its price-to-tangib…
Neurophet Inc has a market capitalization of KRW 205,153,310,890 and a price-to-book ratio of 10.55, indicating a premium valuation relative to its book value. The company's liquidity position is c…
The company maintains a conservative capital structure with a debt-to-equity ratio of 0.1, indicating a low reliance on debt financing. Its liquidity position is characterized by a current ratio of…
Epi Biotech Co Ltd exhibits a distressed capital structure characterized by negative total equity of -11,903,878,350 KRW and total liabilities of 17,201,455,210 KRW, which exceed total assets of 5,…
The company maintains a strong liquidity position, with cash and equivalents amounting to ¥175,466.9 million, representing 81.3% of total assets. The liquidity FPT (free cash flow to total assets)…
The company's capital structure is characterized by a debt-to-equity ratio of 1.58, indicating a relatively high level of leverage. Despite holding KRW 5,238,254,430 in cash and equivalents, the fi…
The company maintains a market price of 962 JPY per share, with a market capitalization of 3,872,121,188 JPY. Its price-to-earnings ratio is 16.05, and its price-to-book ratio is 1.58, indicating a…
The company's capital structure is characterized by a high liquidity position, with cash and equivalents amounting to ¥2.79 billion, significantly exceeding its total liabilities of ¥1.67 billion.…
Ginwa Enterprise Group Inc has a market capitalization of CNY 2.00 billion and a price-to-earnings ratio of 128.44, indicating a high valuation relative to earnings. The company's price-to-book rat…
The company maintains a strong liquidity position, with cash and equivalents amounting to ¥1,562,417,000, representing 65.8% of total assets. The liquidity FPT score indicates a low liquidity risk,…
The company maintains a debt-to-equity ratio of 0.48, indicating a relatively conservative capital structure with a moderate reliance on debt financing. Its current ratio of 2.04 suggests that it h…
6665.TWO maintains a relatively balanced capital structure with a debt-to-equity ratio of 0.3, indicating a conservative approach to leverage. The company's liquidity position is assessed as medium…
6797.TWO has a liquidity position that is currently medium, with a current ratio of 3.04, indicating the company can cover its short-term liabilities with its short-term assets. However, the compan…
6808.TWO has a strong liquidity position, as evidenced by a current ratio of 14.08, indicating that the company holds significantly more current assets than current liabilities. The company's liqui…
The company's capital structure is characterized by a debt-to-equity ratio of 0.35, indicating a relatively conservative leverage position. However, the liquidity risk is assessed as medium, with n…
Pharmosa Biopharm Inc exhibits a strong liquidity position, with cash and equivalents amounting to TWD 11,093,360,000, which is significantly higher than its total liabilities of TWD 216,428,000, r…
The company's capital structure is characterized by a high proportion of equity, with total equity of TWD 155.08 billion and total liabilities of TWD 34.53 billion, resulting in a debt-to-equity ra…
The company maintains a strong liquidity position, with cash and equivalents amounting to ¥4,776,831,000, which is significantly higher than its total liabilities of ¥5,234,554,000. The current rat…
The company maintains a market price of TWD 103, with a market capitalization of TWD 2.3 billion, and a price-to-earnings ratio of 24.23, indicating a moderate valuation relative to earnings. The p…
Light AI Inc operates with a highly liquid balance sheet, as evidenced by a current ratio of 8.67, indicating strong short-term liquidity. The company is entirely equity-funded, with no long-term d…
The company's capital structure is highly leveraged, with a debt-to-equity ratio of 4.17, indicating a significant reliance on debt financing. Despite a negative net cash position after subtracting…
Anatara Lifesciences Ltd maintains a capital structure characterized by significant leverage relative to its equity base, with a debt-to-equity ratio of 0.76. The company holds total assets of 1,14…
ASTB.BO has a debt-to-equity ratio of 0.37, indicating a relatively conservative capital structure with a moderate reliance on debt financing. The company's liquidity position is assessed as medium…
BALP.NS has a debt-to-equity ratio of 1.94, indicating a capital structure that is significantly leveraged, with liabilities exceeding equity by a wide margin. The company's liquidity position is a…
BGETR.BB has a debt-to-equity ratio of 0.8, indicating a relatively balanced capital structure with a moderate reliance on debt financing. The company's liquidity position is characterized as mediu…
BGM Group Ltd has a market capitalization of $48.57 million and a price-to-book ratio of 1.14, indicating that the market values the company slightly above its book value. The company's liquidity p…
BIZ.BK has a market capitalization of 3,093.79 million THB and a price-to-earnings ratio of 10.12, indicating a moderate valuation relative to earnings. The company's price-to-book ratio is 3.18, s…
CHEC.BO has a debt-to-equity ratio of 0.57, indicating a moderate level of leverage, and a current ratio of 2.31, suggesting it has sufficient short-term assets to cover its liabilities. However, t…
CHEK.JK maintains a strong liquidity position with a current ratio of 4.41, indicating the company can easily cover its short-term liabilities with its current assets. The company holds significant…
Genenta Science has a market capitalization of EUR 14.86 million, with a market price of EUR 0.63 per share, based on the latest available valuation data. The company has 23.59 million shares outst…
GNXL.BO maintains a relatively strong liquidity position, with a current ratio of 4.07, indicating that it has sufficient current assets to cover its current liabilities. However, the company repor…
The company's capital structure is characterized by a low debt-to-equity ratio of 0.07, indicating a conservative leverage approach. However, the negative operating and net income of -35.5 million…
Imaging Biometrics Ltd maintains a capital structure characterized by zero long-term debt, resulting in a debt-to-equity ratio of 0.0. However, the company faces significant liquidity constraints,…
Redox International Group Corp has a highly leveraged capital structure, with total liabilities of $30,480 million and total equity of -$25,010 million, resulting in a negative debt-to-equity ratio…
JCT.BK maintains a strong liquidity position with a current ratio of 10.28, indicating a significant buffer of current assets over current liabilities. The company holds THB 171,741,640 in cash and…
KIMI.BO has a liquidity risk profile that is currently rated as medium, with a debt-to-equity ratio of 3.95 and a current ratio of 0.92, indicating that the company's short-term liabilities exceed…
Mevis Medical Solutions AG has a basic and diluted share count of 1,820,000 shares outstanding, indicating no immediate dilution pressure from share-based compensation or convertible instruments. H…
Pensana PLC has a liquidity risk as indicated by a current ratio of 0.07, which is significantly below the industry median, suggesting a weak ability to meet short-term obligations. The company's l…
RTA Laboratuvarlari Biyolojik Urunler Ilac ve Makine Sanayi Ticaret AS maintains a strong liquidity position, with a current ratio of 1.44, indicating the company can cover its short-term liabiliti…
Revvity maintains a capital structure characterized by a debt-to-equity ratio of 0.36, indicating moderate leverage relative to its equity base of $7.25 billion. The company holds $920 million in c…
SAB Biotherapeutics maintains a strong liquidity position, with a current ratio of 9.46, indicating the company can easily cover its short-term liabilities with its current assets. The company's ca…
Scilex Holding Co has a negative net equity of -$207.8 million and a current ratio of 0.08, indicating significant liquidity constraints. The company's cash and equivalents amount to only $4.96 mil…
SIAM.NS maintains a strong liquidity position, with a current ratio of 4.01, indicating that the company has sufficient current assets to cover its current liabilities multiple times over. The comp…
The company's capital structure is highly leveraged, with total liabilities of CAD 36,399,000 and total equity of CAD -2,981,870, indicating a negative net worth. Liquidity is constrained, as evide…
The company's capital structure is characterized by a debt-to-equity ratio of 0.48, indicating a moderate reliance on debt financing. Its liquidity position is assessed as medium, with a current ra…
Shandong Wohua Pharmaceutical Co Ltd maintains a strong liquidity position, with a current ratio of 2.35, indicating that it has more than twice the current assets to cover its current liabilities.…
Handok Inc operates with a debt-to-equity ratio of 1.01, indicating a balanced capital structure, but its liquidity position is rated as medium risk due to negative net cash after subtracting total…
Shandong Xinhua Pharmaceutical Co Ltd has a market capitalization of $120.51 million and a price-to-earnings ratio of 4.16, indicating a relatively low valuation compared to earnings. The company's…
The company maintains a strong liquidity position, with a current ratio of 2.62 and cash and equivalents amounting to 9,999,999,850 KRW. Its debt-to-equity ratio is very low at 0.01, indicating min…
Linical maintains a strong liquidity position with JPY 7.47 billion in cash and equivalents, representing 40.3% of total assets. The company's liquidity FPT score of 0.85 indicates robust short-ter…
The company's capital structure and liquidity position are not fully assessable due to the lack of balance-sheet inputs and no going-concern language in the source documents. However, the shares ou…
Parataxis Korea Inc maintains a strong liquidity position with KRW 13,090,042,310 in cash and equivalents, representing 50% of total assets. The company's liquidity FPT score of 8.2 indicates robus…
The company's capital structure is characterized by a relatively low debt-to-equity ratio of 0.34, indicating a conservative approach to leverage. Despite this, the company's liquidity position is…
The company maintains a relatively strong liquidity position, with a current ratio of 3.42, indicating that it has sufficient current assets to cover its current liabilities. However, the company's…
Guangdong Hybribio Biotech Co Ltd has a market price of 6.16 CNY per share, with a market capitalization of 3.98 billion CNY. The company's price-to-book ratio is 1.06, and its price-to-tangible-bo…
The company maintains a strong liquidity position, with a current ratio of 6.27, indicating that it has sufficient current assets to cover its current liabilities multiple times over. However, the…
WonBiogen maintains a conservative capital structure with a debt-to-equity ratio of 0.21, significantly below the industry median of 0.45, indicating a strong equity position relative to its liabil…
The company maintains a strong liquidity position, with cash and equivalents amounting to ¥5,058,521,000, which represents a significant portion of its total assets. The liquidity FPT (free cash fl…
Modern Dental Group Ltd maintains a conservative capital structure with a debt-to-equity ratio of 0.2, indicating a low reliance on debt financing. The company's liquidity position is characterized…
Curocell Inc has a highly leveraged capital structure, with a debt-to-equity ratio of 11.28, indicating significant reliance on debt financing. The company's liquidity position is weak, as evidence…
The company's capital structure is characterized by a debt-to-equity ratio of 0.77, indicating a moderate reliance on debt financing. Its liquidity position is assessed as medium, with a current ra…
The company's capital structure is characterized by a debt-to-equity ratio of 0.28, indicating a relatively low reliance on debt financing compared to equity. However, the liquidity position is ass…
The company's capital structure is characterized by a market price of 17.15 TWD per share and a market capitalization of 726.71 million TWD. The price-to-book ratio is 1.24, indicating that the mar…
NeoCore Technology Co Ltd has a capital structure with a debt-to-equity ratio of 0.26, indicating a relatively low reliance on debt financing compared to equity. The company's liquidity position is…
Zhejiang Shapuaisi Pharmaceutical Co Ltd has a market price of 5.92 CNY per share, with a market capitalization of 2,214,828,909.6 CNY. The company's price-to-book ratio is 1.31, and its price-to-t…
The company's capital structure is characterized by a debt-to-equity ratio of 0.78, indicating a moderate level of leverage. The liquidity position is assessed as medium, with a current ratio of 1.…
The company's capital structure is characterized by a debt-to-equity ratio of 0.63, indicating a moderate reliance on debt financing. Its liquidity position is assessed as medium, with a current ra…
The company's capital structure is characterized by a debt-to-equity ratio of 1.27, indicating a moderate reliance on debt financing. With a market cap of 592.5 million TWD and an enterprise value…
Aelis Farma has a fully diluted share count of 13,706,586 shares, with no difference between basic and diluted shares outstanding, indicating no dilution risk from stock options or convertible inst…
The company exhibits a distressed capital structure with negative total equity of -28.19 million GBP and total liabilities of 95.74 million GBP exceeding total assets of 67.54 million GBP. Long-ter…
Apimeds Pharmaceuticals US Inc has a highly leveraged capital structure, with a debt-to-equity ratio of 8.37, indicating a significant reliance on debt financing. The company's liquidity position i…
Arcturus Therapeutics operates with a strong liquidity position, as evidenced by its cash and equivalents of $230.91 million, which significantly exceeds its total liabilities of $57.16 million, re…
BACTIQ.CO has a market capitalization of DKK 119,319,502 and a price-to-book ratio of 6.91, indicating that the market is valuing the company at a premium to its book value. The company's liquidity…
Vi sender deg én e-post når Handelsavisen lanseres. Ingen spam, ingen annen bruk.
Ved å registrere deg samtykker du til å motta ett enkelt varsel fra Handelsavisen på lanseringsdagen.